Restricted accessOtherFirst published online 2015-4
Comment on severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody
LebarRLubetzkiCVincentC. The M2 autoantigen of central nervous system myelin, a glycoprotein present in oligodendrocyte membrane. Clin Exp Immunol1986; 66: 423–434.
2.
Pham-DinhDMatteiMGNussbaumJL. Myelin/oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex. Proc Natl Acad Sci U S A1993; 90: 7990–7994.
3.
BrunnerCLassmannHWaehneldtTV. Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2’,3’-cyclic nucleotide 3’-phosphodiesterase in the CNS of adult rats. J Neurochem1989; 52: 296–304.
4.
RauerSEulerBReindlM. Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psychiatry2006; 77: 739–742.
5.
PelayoRTintoreMMontalbanX. Antimyelin antibodies with no progression to multiple sclerosis. New Engl J Med2007; 356: 426–428.
6.
ReindlMDi PauliFRostasyK. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol2013; 9: 455–461.
7.
MayerMCBreithauptCReindlM. Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol2013; 191: 3594–3604.
8.
OlssonT.White matter disease: Roles of anti-MOG antibodies in demyelinating diseases. Nat Rev Neurol2011; 7: 248–249.
9.
WingerchukDMLennonVAPittockSJ. Revised diagnostic criteria for neuromyelitis optica. Neurology2006; 66: 1485–1489.
10.
MaderSGredlerVSchandaK. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflamm2011; 8: 184.
11.
KitleyJWoodhallMWatersP. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology2012; 79: 1273–1277.
12.
KitleyJWatersPWoodhallM. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: A comparative study. JAMA Neurol2014; 71: 276–283.
13.
SatoDKCallegaroDLana-PeixotoMA. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology2014; 82: 474–481.
14.
TakanoRMisuTTakahashiT. Astrocytic damage is far more severe than demyelination in NMO: A clinical CSF biomarker study. Neurology2010; 75: 208–216.
15.
BradlMLassmannDH.Anti-aquaporin-4 antibodies in neuromyelitis optica: How to prove their pathogenetic relevance?Int MS J/ MS Forum2008; 15: 75–78.
16.
RostasyKMaderSHennesEM. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler2013; 19: 1052–1059.
